SGHT (Sight Sciences) Moat Score: 3/10 (As of Jun. 29, 2026)


SGHT Sight Sciences Inc SGHT
71 GF Score
Price $5.67
GF Value $4.49
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sight Sciences Moat Score?

Sight Sciences SGHT +4.50% 71 Moat Score is 3 as of Jun. 29, 2026. GuruFocus rates SGHT with a GF Score™ of 71/100 and a GF Value™ of $4.49 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Sight Sciences ranks better than 75.89% on this metric.

Sight Sciences has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Sight Sciences has No Moat: Sight Sciences Inc has limited market leadership and lacks significant customer switching costs or strong brand loyalty. The company operates in a competitive medical device industry with minimal regulatory barriers and no significant cost advantages or intellectual property that would provide a durable competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sight Sciences might have No Moat - Very weak/transient advantages.

Sight Sciences  (NAS:SGHT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sight Sciences Moat Score Related Terms

SGHT vs SENS, LAB, TMCI: Moat Score Comparison

For the Medical Devices subindustry, Sight Sciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sight Sciences Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Sight Sciences's Moat Score falls into.


SGHT
71GF Score
Sight Sciences Inc SGHT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Sight Sciences (SGHT) has a Moat Score of 3 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sight Sciences ranks #204 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 24.1%.
Is Sight Sciences' Moat Score too high?
Sight Sciences' current Moat Score is 3. Based on the distribution chart, Sight Sciences ranks #204 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sight Sciences has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Moat Score compare to SENS and LAB?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #204 out of 846 companies for Moat Score. This places Sight Sciences in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Sight Sciences's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.49, compared to a current price of $5.67 — trading 26.3% above its estimated fair value. The current Moat Score is 3. Sight Sciences' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Moat Score is 3 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sight Sciences (SGHT) Overvalued in 2026?

Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued. The current stock price of $5.67 is trading 26.3% above its estimated GF Value™ of $4.49. GuruFocus considers Sight Sciences to be Modestly Overvalued.

Key valuation signals for SGHT:

  • Moat Score: 3
  • GF Value™: $4.49 vs. price of $5.67 (26.3% above fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sight Sciences Business Description

Address 4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
71GF Score

Get the complete analysis for SGHT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.67
Price
$4.49
GF Value